ACOR Split History

Acorda Therapeutics (ACOR) has 1 split in our ACOR split history database. The split for ACOR took place on January 04, 2021. This was a 1 for 6 reverse split, meaning for each 6 shares of ACOR owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 166.666666666667 share position following the split.

When a company such as Acorda Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the ACOR split history from start to finish, an original position size of 1000 shares would have turned into 166.666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Acorda Therapeutics shares, starting with a $10,000 purchase of ACOR, presented on a split-history-adjusted basis factoring in the complete ACOR split history.

Growth of $10,000.00 Without Dividends Reinvested
Start date:	03/26/2013
End date:	03/23/2023
Start price/share:	$187.26
End price/share:	$0.57
Dividends collected/share:	$0.00
Total return:	-99.70%
Average Annual Total Return:	-43.99%
Starting investment:	$10,000.00
Ending investment:	$30.43
Years:	10.00

About Acorda Therapeutics

Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Co. markets Inbrija (levodopa inhalation powder), which is approved for intermittent treatment of episodic motor fluctuations, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija utilizes Co.'s ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Co. also markets Ampyra (dalfampridine) extended release tablets, 10 mg for improving walking in patients with multiple sclerosis. Ampyra is marketed as Fampyra outside the U.S. According to our ACOR split history records, Acorda Therapeutics has had 1 split.